Bromhexine (hydrochloride)

Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC50 of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions[1][2][3][4].

Product Specifications

CAS Number

[611-75-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; HIV; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Autophagy

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Bromhexine-hydrochloride.html

Concentration

10mM

Purity

99.93

Solubility

DMSO : 20 mg/mL (ultrasonic) |H2O : 3.33 mg/mL (ultrasonic)

Smiles

CN(C1CCCCC1)CC2=CC(Br)=CC(Br)=C2N.Cl

Molecular Formula

C14H21Br2ClN2

Molecular Weight

412.59

Precautions

H302, H315, H319, H335

References & Citations

[1]Jared M Lucas, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014 Nov;4 (11) :1310-25.|[2]Li Wen Shen, et al. TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections. Biochimie. 2017 Nov;142:1-10.|[3]Roberto Maggio, et al. Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection. Pharmacol Res. 2020 Jul;157:104837.|[4]Santosh Chauhan, et al. Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential. Nat Commun. 2015 Oct 27;6:8620.